MTBVAC in Newborns: kick-off meeting in South Africa
The kick-off meeting of the EDCTP-funded project MTBVAC in Newborns took place in Cape Town, South Africa on 6-7 June 2018. The candidate TB vaccine MTBVAC was developed by researchers from the University of Zaragoza, Spain, and the Institut Pasteur in Paris, France. The project, coordinated by Ingrid Murillo of the biopharmaceutical company Biofabri S.L. includes a phase IIa dose-defining safety and immunogenicity trial of candidate TB vaccine MTBVAC in South African newborns while at the same time building research capacity to support vaccine efficacy trials in sub-Saharan Africa.